Novartis has received regulatory approval from Swissmedic, Switzerland's medical products authority, for Coartem Baby, the world's first malaria treatment specifically designed for newborns and young children. This approval marks a milestone in the global fight against malaria, a disease that caused approximately 597,000 deaths worldwide in 2023, with the vast majority occurring in African children under five years old. Coartem Baby is a lower-dose formulation of a previously approved antimalarial combination (Artemether-Lumefantrine) and features a dissolvable, cherry-flavored formula that can be mixed with milk to facilitate administration to infants. The drug is expected to be rolled out in several African countries, including Burkina Faso, Ivory Coast, Kenya, Malawi, Mozambique, Nigeria, Tanzania, and Uganda, within weeks. Experts highlight that this treatment could help reduce healthcare access inequalities and save thousands of young lives by providing a clinically tested option for malaria treatment in infants and very young children.